Americhem Launches EcoLube™ MD PFAS-Free Internally Lubricated Compounds for Healthcare Applications
Americhem, Inc., a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has launched the EcoLube™ MD line of PFAS-free internally lubricated compounds specifically for medical devices and other healthcare applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250129921412/en/
EcoLube™ MD Pre-lubricated Engineered Compounds (Photo: Business Wire)
Building on the success of Americhem’s launch of EcoLube™ in 2024, EcoLube™ MD offers significant advantages for healthcare applications. As a sustainable, non-PFAS solution, EcoLube™ MD addresses the critical need for effective wear and friction reduction. It ensures compliance with current and future regulations, demonstrates environmental stewardship, and reduces environmental impact.
EcoLube™ MD pre-lubricated engineered compounds and alloys are designed to help manufacturers reduce the wear and friction of moving plastic parts, reduce noise during use, and decrease the coefficient of friction for plastic-on-plastic and plastic-on-metal applications, all without the use of PFAS components. End-use applications can include minimally invasive surgical devices, syringe pumps, prosthetics, surgical robots, and more.
Matt Miklos, Vice President/General Manager of Americhem’s engineered compounds division, noted that healthcare OEMs are increasingly concerned about sustainability and ensuring that new products meet current and future regulations.
“With regulations around the world potentially restricting or banning the use of PFAS and PTFE, healthcare OEMs are challenged with finding alternatives that can match their self-lubricating performance,” said Miklos. “Our new PFAS-free EcoLube™ MD line showcases Americhem's dedication to innovation, meeting their unique needs and helping them stay ahead in their respective markets.”
Enhancing Medical Devices with Rigorous Material Performance and Compliance
Linda Boyett, Vice President of Global Technology & Innovation at Americhem, said Ecolube™ MD has undergone testing for performance and biocompatibility. Internal testing has indicated similar performance to the more traditional internal lubricants and wear resistant additives in most cases. Ecolube™ MD has undergone ISO10993 –5 testing for biocompatibility as part of the global medical compliance certifications.
“ISO10993 – 5 testing for biocompatibility is an important global medical compliance certification, and we’re proud that EcoLube™ MD is a proven solution that supports sustainability and performance for the healthcare industry,” said Boyett.
EcoLube™ Family of Lubricants
EcoLube™ shatters the limitations of conventional lubrication, ushering in a new era of embedded performance. This revolutionary technology integrates specially designed functional additives directly into the material, providing long-lasting lubrication from within. A variety of functional additives cater to specific applications, resulting in a versatile EcoLube™ product line capable of tackling a wide range of lubrication challenges.
- Solid state, non-migrating lubricants that stand up to extreme pressures, reducing frictional wear and "slip-stick" behavior in nylon bearings.
- Multifunctional, migrating, boundary lubricants reduce the coefficient of friction and wear rate by providing immediate lubrication at start-up and high speeds.
- Non-traditional formulations offer shear reinforcement and abrasion resistance between moving, mating parts.
- Low friction, non-migratory additives are designed to offset PTFE in various applications and thermoplastics.
- Ecolube™ MD biocompatibility testing and compliance with the medical certifications are coupled with AEC’s stringent Process Change Management commitments and locked formulation promise make it an easy choice for a variety of medical applications.
A Wide Range of Base Resins
Americhem has formulated EcoLube™ compounds in a wide variety of base resins, including ABS, PBT, PCABS, PC, PEI, PPE, PPS, PE, PP, PSU, PPSU, POM, PEEK, PPA, PA, and TPU.
“We pride ourselves on our ability to customize products to fit end-market performance, conversion processes, color, and aesthetic requirements. By working closely with our customers, we shape specifications and new technologies to meet their unique needs and sustainability objectives,” added Miklos.
About Americhem
Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129921412/en/
Contacts
Stephanie Sulcer
Director, Marketing & Communications
sasulcer@americhem.com
+1 (330) 810-0977
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 202531.1.2025 15:30:00 EET | Press release
Coincheck Group N.V. (the “Company”) (Nasdaq: CNCK), the holding company for Coincheck, Inc, a leading Japanese crypto exchange, today announced that the Company will release its third quarter 2025 financial results on Wednesday, February 12, 2025. The Company will host a conference call to discuss third quarter 2025 financial results at 5:00 pm ET that same day. Hosting the call will be Oki Matsumoto, Executive Chairman, Gary Simanson, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer. The call will be webcast live from the Company's website at www.coincheckgroup.com. A replay will be available on the Company’s investor relations website following the call. The conference call can also be accessed over the phone by dialing (877) 407-4018 or (201) 689-8471; the Conference ID is 13751285. About Coincheck Group N.V. Headquartered in the Netherlands, Coincheck Group N.V. (NASDAQ: CNCK) is a public limited liability company and the holding company for Coincheck, Inc. Coi
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer31.1.2025 15:00:00 EET | Press release
Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE:45680) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast01 phase 3 trial published in the Journal of Clinical Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast01, datopot
REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 202531.1.2025 13:42:00 EET | Press release
Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/ Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire) The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom